The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma—A comparison with leukotriene D4 induced broncoconstriction
Abstract The bronchoconstriction caused by inhaled neurokinin A (NKA) in patients with asthma is indirect. The mediators involved in NKA-induced bronchoconstriction are unknown. Studies with various H1 receptor antagonists were negative, making an important contribution of histamine unlikely. To stu...
Gespeichert in:
| Veröffentlicht in: | Pulmonary pharmacology & therapeutics 2008-04, Vol.21 (2), p.276-284 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 284 |
|---|---|
| container_issue | 2 |
| container_start_page | 276 |
| container_title | Pulmonary pharmacology & therapeutics |
| container_volume | 21 |
| creator | Schelfhout, V Van De Velde, V Pauwels, R Joos, G |
| description | Abstract The bronchoconstriction caused by inhaled neurokinin A (NKA) in patients with asthma is indirect. The mediators involved in NKA-induced bronchoconstriction are unknown. Studies with various H1 receptor antagonists were negative, making an important contribution of histamine unlikely. To study the role of cysteinyl leukotrienes in neurokinin A-induced bronchoconstriction, we performed a randomised, double-blind, cross-over, placebo controlled trial in 12 patients with mild to moderate asthma. Zafirlukast and matching placebo were given orally, 40 mg the evening before and 40 mg the morning of assessment. In one period NKA was administered, in the other period leukotriene D4 (LTD4 ). Increasing concentrations of NKA and LTD4 were inhaled from a 30 L bag, after nebulization via a Mallinckrodt nebuliser. The difference between log10 PC20 LTD4 after treatment with placebo or zafirlukast was highly significant ( p |
| doi_str_mv | 10.1016/j.pupt.2007.05.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70369355</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1094553907000466</els_id><sourcerecordid>70369355</sourcerecordid><originalsourceid>FETCH-LOGICAL-c271t-b026df4351f7fb27c568e18d5ea2132a341ed301a6ef9712bd4b0043feda5abd3</originalsourceid><addsrcrecordid>eNpVkUtuFDEQhr0AkTDhAiyQV-y68aMfmQ3SKDylSFkkrC23u8x4pttubHdQWOUQuQ934SRUMyORrGyr_vrkqo-Q15yVnPHm3a6c5imXgrG2ZHXJmHxGTjlbV0Vdy_UJeZnSjmGxkvULcsLbhnMuxSn5fbMFCtaCyTRYmvE1wLwPOTrwQCMYmHKIVPusvwfvUqa_tHVxmPca78FTD3MMe-edp5vC-X420NMuBm-2wQSfkGSywyAGJp0RmxP96fKWImA76j_3Dxtqwjjp6BLG_pUe_-FDRZ9gn1DPyHOrhwSvjueKfPv08ebiS3F59fnrxeayMKLlueiYaHqLw3Pb2k60pm7OgZ_3NWiBe9Cy4tBLxnUDdt1y0fVVx1glLfS61l0vV-TtgTvF8GOGlNXokoFh0B7CnFTLZLOWuOsVEYegiSGlCFZN0Y063inO1KJK7dSiSi2qFKsVqsKmN0f63I3Q_285esLA-0MAcMZbB1GZAVdu9LCHO0i7MEeP4yuuklBMXS_mF_GsRelV08i_3IevvA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70369355</pqid></control><display><type>article</type><title>The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma—A comparison with leukotriene D4 induced broncoconstriction</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Schelfhout, V ; Van De Velde, V ; Pauwels, R ; Joos, G</creator><creatorcontrib>Schelfhout, V ; Van De Velde, V ; Pauwels, R ; Joos, G</creatorcontrib><description>Abstract The bronchoconstriction caused by inhaled neurokinin A (NKA) in patients with asthma is indirect. The mediators involved in NKA-induced bronchoconstriction are unknown. Studies with various H1 receptor antagonists were negative, making an important contribution of histamine unlikely. To study the role of cysteinyl leukotrienes in neurokinin A-induced bronchoconstriction, we performed a randomised, double-blind, cross-over, placebo controlled trial in 12 patients with mild to moderate asthma. Zafirlukast and matching placebo were given orally, 40 mg the evening before and 40 mg the morning of assessment. In one period NKA was administered, in the other period leukotriene D4 (LTD4 ). Increasing concentrations of NKA and LTD4 were inhaled from a 30 L bag, after nebulization via a Mallinckrodt nebuliser. The difference between log10 PC20 LTD4 after treatment with placebo or zafirlukast was highly significant ( p <0.0001). A trend was observed towards a difference between log10 PC20 neurokinin A after treatment with placebo or zafirlukast ( p =0.0741). The dose ratio for the neurokinin A provocation was 4.4 and for the LTD4 provocation 67.7. In conclusion, zafirlukast had a large inhibitory effect on LTD4 -induced bronchoconstriction, but offered only limited protective effect against neurokinin A-induced bronchoconstriction. We suggest that leukotrienes play a limited role in the bronchoconstrictor effect of neurokinin A in patients with asthma.</description><identifier>ISSN: 1094-5539</identifier><identifier>DOI: 10.1016/j.pupt.2007.05.003</identifier><identifier>PMID: 17611132</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Arachidonate 5-Lipoxygenase - genetics ; Asthma - physiopathology ; Bronchial Provocation Tests ; Bronchoconstriction - drug effects ; Cross-Over Studies ; Dose-Response Relationship, Drug ; Double-Blind Method ; Glutathione Transferase - genetics ; Humans ; Leukotriene Antagonists - pharmacology ; Leukotriene D4 - antagonists & inhibitors ; Leukotriene D4 - pharmacology ; Leukotriene D4 - physiology ; Medical Education ; Neurokinin A - antagonists & inhibitors ; Neurokinin A - pharmacology ; Neurokinin A - physiology ; Polymorphism, Genetic ; Pulmonary/Respiratory ; Tosyl Compounds - pharmacology</subject><ispartof>Pulmonary pharmacology & therapeutics, 2008-04, Vol.21 (2), p.276-284</ispartof><rights>Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c271t-b026df4351f7fb27c568e18d5ea2132a341ed301a6ef9712bd4b0043feda5abd3</citedby><cites>FETCH-LOGICAL-c271t-b026df4351f7fb27c568e18d5ea2132a341ed301a6ef9712bd4b0043feda5abd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17611132$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schelfhout, V</creatorcontrib><creatorcontrib>Van De Velde, V</creatorcontrib><creatorcontrib>Pauwels, R</creatorcontrib><creatorcontrib>Joos, G</creatorcontrib><title>The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma—A comparison with leukotriene D4 induced broncoconstriction</title><title>Pulmonary pharmacology & therapeutics</title><addtitle>Pulm Pharmacol Ther</addtitle><description>Abstract The bronchoconstriction caused by inhaled neurokinin A (NKA) in patients with asthma is indirect. The mediators involved in NKA-induced bronchoconstriction are unknown. Studies with various H1 receptor antagonists were negative, making an important contribution of histamine unlikely. To study the role of cysteinyl leukotrienes in neurokinin A-induced bronchoconstriction, we performed a randomised, double-blind, cross-over, placebo controlled trial in 12 patients with mild to moderate asthma. Zafirlukast and matching placebo were given orally, 40 mg the evening before and 40 mg the morning of assessment. In one period NKA was administered, in the other period leukotriene D4 (LTD4 ). Increasing concentrations of NKA and LTD4 were inhaled from a 30 L bag, after nebulization via a Mallinckrodt nebuliser. The difference between log10 PC20 LTD4 after treatment with placebo or zafirlukast was highly significant ( p <0.0001). A trend was observed towards a difference between log10 PC20 neurokinin A after treatment with placebo or zafirlukast ( p =0.0741). The dose ratio for the neurokinin A provocation was 4.4 and for the LTD4 provocation 67.7. In conclusion, zafirlukast had a large inhibitory effect on LTD4 -induced bronchoconstriction, but offered only limited protective effect against neurokinin A-induced bronchoconstriction. We suggest that leukotrienes play a limited role in the bronchoconstrictor effect of neurokinin A in patients with asthma.</description><subject>Adult</subject><subject>Arachidonate 5-Lipoxygenase - genetics</subject><subject>Asthma - physiopathology</subject><subject>Bronchial Provocation Tests</subject><subject>Bronchoconstriction - drug effects</subject><subject>Cross-Over Studies</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Glutathione Transferase - genetics</subject><subject>Humans</subject><subject>Leukotriene Antagonists - pharmacology</subject><subject>Leukotriene D4 - antagonists & inhibitors</subject><subject>Leukotriene D4 - pharmacology</subject><subject>Leukotriene D4 - physiology</subject><subject>Medical Education</subject><subject>Neurokinin A - antagonists & inhibitors</subject><subject>Neurokinin A - pharmacology</subject><subject>Neurokinin A - physiology</subject><subject>Polymorphism, Genetic</subject><subject>Pulmonary/Respiratory</subject><subject>Tosyl Compounds - pharmacology</subject><issn>1094-5539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtuFDEQhr0AkTDhAiyQV-y68aMfmQ3SKDylSFkkrC23u8x4pttubHdQWOUQuQ934SRUMyORrGyr_vrkqo-Q15yVnPHm3a6c5imXgrG2ZHXJmHxGTjlbV0Vdy_UJeZnSjmGxkvULcsLbhnMuxSn5fbMFCtaCyTRYmvE1wLwPOTrwQCMYmHKIVPusvwfvUqa_tHVxmPca78FTD3MMe-edp5vC-X420NMuBm-2wQSfkGSywyAGJp0RmxP96fKWImA76j_3Dxtqwjjp6BLG_pUe_-FDRZ9gn1DPyHOrhwSvjueKfPv08ebiS3F59fnrxeayMKLlueiYaHqLw3Pb2k60pm7OgZ_3NWiBe9Cy4tBLxnUDdt1y0fVVx1glLfS61l0vV-TtgTvF8GOGlNXokoFh0B7CnFTLZLOWuOsVEYegiSGlCFZN0Y063inO1KJK7dSiSi2qFKsVqsKmN0f63I3Q_285esLA-0MAcMZbB1GZAVdu9LCHO0i7MEeP4yuuklBMXS_mF_GsRelV08i_3IevvA</recordid><startdate>200804</startdate><enddate>200804</enddate><creator>Schelfhout, V</creator><creator>Van De Velde, V</creator><creator>Pauwels, R</creator><creator>Joos, G</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200804</creationdate><title>The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma—A comparison with leukotriene D4 induced broncoconstriction</title><author>Schelfhout, V ; Van De Velde, V ; Pauwels, R ; Joos, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c271t-b026df4351f7fb27c568e18d5ea2132a341ed301a6ef9712bd4b0043feda5abd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Arachidonate 5-Lipoxygenase - genetics</topic><topic>Asthma - physiopathology</topic><topic>Bronchial Provocation Tests</topic><topic>Bronchoconstriction - drug effects</topic><topic>Cross-Over Studies</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Glutathione Transferase - genetics</topic><topic>Humans</topic><topic>Leukotriene Antagonists - pharmacology</topic><topic>Leukotriene D4 - antagonists & inhibitors</topic><topic>Leukotriene D4 - pharmacology</topic><topic>Leukotriene D4 - physiology</topic><topic>Medical Education</topic><topic>Neurokinin A - antagonists & inhibitors</topic><topic>Neurokinin A - pharmacology</topic><topic>Neurokinin A - physiology</topic><topic>Polymorphism, Genetic</topic><topic>Pulmonary/Respiratory</topic><topic>Tosyl Compounds - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schelfhout, V</creatorcontrib><creatorcontrib>Van De Velde, V</creatorcontrib><creatorcontrib>Pauwels, R</creatorcontrib><creatorcontrib>Joos, G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pulmonary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schelfhout, V</au><au>Van De Velde, V</au><au>Pauwels, R</au><au>Joos, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma—A comparison with leukotriene D4 induced broncoconstriction</atitle><jtitle>Pulmonary pharmacology & therapeutics</jtitle><addtitle>Pulm Pharmacol Ther</addtitle><date>2008-04</date><risdate>2008</risdate><volume>21</volume><issue>2</issue><spage>276</spage><epage>284</epage><pages>276-284</pages><issn>1094-5539</issn><abstract>Abstract The bronchoconstriction caused by inhaled neurokinin A (NKA) in patients with asthma is indirect. The mediators involved in NKA-induced bronchoconstriction are unknown. Studies with various H1 receptor antagonists were negative, making an important contribution of histamine unlikely. To study the role of cysteinyl leukotrienes in neurokinin A-induced bronchoconstriction, we performed a randomised, double-blind, cross-over, placebo controlled trial in 12 patients with mild to moderate asthma. Zafirlukast and matching placebo were given orally, 40 mg the evening before and 40 mg the morning of assessment. In one period NKA was administered, in the other period leukotriene D4 (LTD4 ). Increasing concentrations of NKA and LTD4 were inhaled from a 30 L bag, after nebulization via a Mallinckrodt nebuliser. The difference between log10 PC20 LTD4 after treatment with placebo or zafirlukast was highly significant ( p <0.0001). A trend was observed towards a difference between log10 PC20 neurokinin A after treatment with placebo or zafirlukast ( p =0.0741). The dose ratio for the neurokinin A provocation was 4.4 and for the LTD4 provocation 67.7. In conclusion, zafirlukast had a large inhibitory effect on LTD4 -induced bronchoconstriction, but offered only limited protective effect against neurokinin A-induced bronchoconstriction. We suggest that leukotrienes play a limited role in the bronchoconstrictor effect of neurokinin A in patients with asthma.</abstract><cop>England</cop><pmid>17611132</pmid><doi>10.1016/j.pupt.2007.05.003</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1094-5539 |
| ispartof | Pulmonary pharmacology & therapeutics, 2008-04, Vol.21 (2), p.276-284 |
| issn | 1094-5539 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70369355 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Arachidonate 5-Lipoxygenase - genetics Asthma - physiopathology Bronchial Provocation Tests Bronchoconstriction - drug effects Cross-Over Studies Dose-Response Relationship, Drug Double-Blind Method Glutathione Transferase - genetics Humans Leukotriene Antagonists - pharmacology Leukotriene D4 - antagonists & inhibitors Leukotriene D4 - pharmacology Leukotriene D4 - physiology Medical Education Neurokinin A - antagonists & inhibitors Neurokinin A - pharmacology Neurokinin A - physiology Polymorphism, Genetic Pulmonary/Respiratory Tosyl Compounds - pharmacology |
| title | The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma—A comparison with leukotriene D4 induced broncoconstriction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A10%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20the%20leukotriene%20receptor%20antagonist%20zafirlukast%20on%20neurokinin%20A-induced%20bronchoconstriction%20in%20patients%20with%20asthma%E2%80%94A%20comparison%20with%20leukotriene%20D4%20induced%20broncoconstriction&rft.jtitle=Pulmonary%20pharmacology%20&%20therapeutics&rft.au=Schelfhout,%20V&rft.date=2008-04&rft.volume=21&rft.issue=2&rft.spage=276&rft.epage=284&rft.pages=276-284&rft.issn=1094-5539&rft_id=info:doi/10.1016/j.pupt.2007.05.003&rft_dat=%3Cproquest_cross%3E70369355%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70369355&rft_id=info:pmid/17611132&rft_els_id=1_s2_0_S1094553907000466&rfr_iscdi=true |